Cantor Fitzgerald raised the firm’s price target on Elutia to $11 from $5 and keeps an Overweight rating on the shares following the firm’s model update that considers the company’s FDA approval for EluPro. Elutia expects to soft launch the product over the coming months, with a full-scale launch anticipated in January 2025, Cantor notes.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELUT:
- Aziyo Biologics Gains FDA Clearance for EluPro® Bioenvelope
- Elutia to sell 3.18M shares at $3.40 in registered direct offering
- Elutia announces FDA clearance of EluPro
- Elutia Announces FDA Clearance of EluPro®: The First Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Implantable Cardiac Pacemakers and Defibrillators
- Elutia Announces $13.26 Million Registered Direct Offering